83 related articles for article (PubMed ID: 32503948)
1. Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503948
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Patil NS; Zou W; Mocci S; Sandler A; Ballinger M; Flynn S; Kowanetz M; Hegde PS
PLoS One; 2021; 16(2):e0246486. PubMed ID: 33534859
[TBL] [Abstract][Full Text] [Related]
3. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
Fukuokaya W; Akazawa K; Kimura T
Anticancer Res; 2024 May; 44(5):2117-2123. PubMed ID: 38677745
[TBL] [Abstract][Full Text] [Related]
4. Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.
Mhatre SK; Machado RJM; Ton TGN; Trinh H; Mazieres J; Rittmeyer A; Bretscher MT
Clin Pharmacol Ther; 2023 Dec; 114(6):1313-1322. PubMed ID: 37696652
[TBL] [Abstract][Full Text] [Related]
5. The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials.
Robesti D; Nocera L; Belladelli F; Schultz JG; Fallara G; Marandino L; Raggi D; Montorsi F; Msaouel P; Necchi A; Martini A
BJU Int; 2024 Feb; 133(2):158-168. PubMed ID: 37422731
[TBL] [Abstract][Full Text] [Related]
6. Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.
Bonanno L; Calvetti L; Dal Maso A; Pavan A; Bao LC; De Nuzzo M; Frega S; Sartori G; Ferro A; Pasello G; Morandi P; Aprile G; Guarneri V
Front Immunol; 2024; 15():1353889. PubMed ID: 38322260
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive impact of molecular tumor burden index in non-small cell lung cancer patients.
Yang F; Tang M; Cui L; Bai J; Yu J; Gao J; Nie X; Li X; Xia X; Yi X; Zhang P; Li L
Thorac Cancer; 2023 Nov; 14(31):3097-3107. PubMed ID: 37724484
[TBL] [Abstract][Full Text] [Related]
8. Potential synergistic effects of cranial radiotherapy and atezolizumab in non-small cell lung cancer: an analysis of individual patient data from seven prospective trials.
Guo T; Zhou Y; Liang F; Wang Z; Bourbonne V; Käsmann L; Sundahl N; Wu AJ; Ni J; Zhu Z
Transl Lung Cancer Res; 2024 Jan; 13(1):126-138. PubMed ID: 38404989
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.
Shemesh CS; Chan P; Legrand FA; Shames DS; Das Thakur M; Shi J; Bailey L; Vadhavkar S; He X; Zhang W; Bruno R
Pharmacol Res Perspect; 2020 Dec; 8(6):e00685. PubMed ID: 33241650
[TBL] [Abstract][Full Text] [Related]
10. Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
Saal J; Bald T; Eckstein M; Ralser DJ; Brossart P; Ellinger J; Hölzel M; Klümper N
Lung Cancer; 2024 Mar; 189():107505. PubMed ID: 38367405
[TBL] [Abstract][Full Text] [Related]
11. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
Tinsley N; Zhou C; Tan G; Rack S; Lorigan P; Blackhall F; Krebs M; Carter L; Thistlethwaite F; Graham D; Cook N
Oncologist; 2020 Jan; 25(1):55-63. PubMed ID: 31292268
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.
Gonçalves A; Marchand M; Chan P; Jin JY; Guedj J; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):68-78. PubMed ID: 37877248
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors.
Saal J; Ellinger J; Ritter M; Brossart P; Hölzel M; Klümper N; Bald T
Clin Transl Immunology; 2023; 12(11):e1472. PubMed ID: 37946873
[TBL] [Abstract][Full Text] [Related]
14. Effect of Concomitant Use of Proton Pump Inhibitors on Immunotherapy Clinical Response in Advanced Cancer Patients: Real-Life Setting.
Cantarelli L; Gutiérrez Nicolás F; García Gil S; Morales Barrios JA; Oramas Rodriguez J; Nazco Casariego GJ
J Immunother; 2023 Nov; ():. PubMed ID: 37937583
[TBL] [Abstract][Full Text] [Related]
15. Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.
Nicolò E; Tarantino P; D'Ecclesiis O; Antonarelli G; Boscolo Bielo L; Marra A; Gandini S; Crimini E; Giugliano F; Zagami P; Corti C; Trapani D; Morganti S; Criscitiello C; Locatelli M; Belli C; Esposito A; Minchella I; Cristofanilli M; Tolaney SM; Curigliano G
Oncologist; 2024 Jan; 29(1):75-83. PubMed ID: 37548439
[TBL] [Abstract][Full Text] [Related]
16. Determining the prognosis of Lung cancer from mutated genes using a deep learning survival model: a large multi-center study.
Peng J; Xiao L; Zhu H; Han L; Ma H
Cancer Cell Int; 2023 Nov; 23(1):262. PubMed ID: 37925409
[TBL] [Abstract][Full Text] [Related]
17. Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302.
Sheng Y; Teng SW; Wang J; Wang H; Tse AN
CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):437-448. PubMed ID: 38111189
[TBL] [Abstract][Full Text] [Related]
18. Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials.
Guo T; Zhou Y; Liang F; Wang Z; Bourbonne V; Käsmann L; Sundahl N; Jing-Ching Wu A; Ni J; Zhu Z
Cancer Commun (Lond); 2024 Feb; 44(2):278-281. PubMed ID: 38145967
[No Abstract] [Full Text] [Related]
19. Atezolizumab in advanced non-small cell lung cancer.
Ilie M; Hofman P
J Thorac Dis; 2017 Oct; 9(10):3603-3606. PubMed ID: 29268352
[No Abstract] [Full Text] [Related]
20. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
Kyte JA; Røssevold A; Falk RS; Naume B
J Transl Med; 2020 Jun; 18(1):252. PubMed ID: 32576225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
